X4 Pharmaceuticals Inc (NASDAQ:XFOR) traded at $0.92 at close of the session on Monday, March 18, made a downward move of -0.46% on its previous day’s price.
Looking at the stock we see that its previous close was $0.93 and the beta (5Y monthly) reads 0.44 . In terms of its 52-week price range, XFOR has a high of $2.58 and a low of $0.57. The company’s stock has lost about -2.40% over that past 30 days.
X4 Pharmaceuticals Inc has a market cap of $154.46 million and is expected to release its quarterly earnings report on Mar 21, 2024. Estimates by analysts give the company expected earnings per share (EPS) of -$0.15, with the EPS growth for the year raised at -$0.63 for 2023 and -$0.45 for next year. These figures represent 58.60% and 28.60% growth in EPS for the two years respectively.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the XFOR stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of Hold.
Looking further, we note the current price level is 0.08% off its SMA20 and 6.19% from its 50-day simple moving average. The RSI (14) is pointing at 52.18 while the volatility over the past week is 8.77% and jumps to 7.90% over the past one month. The beta value is 0.44, while the average true range (ATR) is currently pointing at 0.07.
Coming back to X4 Pharmaceuticals Inc (NASDAQ:XFOR), we note that the average 3-month trading volume was 1.40 million, while that of the preceding 10-day period stands at 1.68 million. Current shares outstanding are 121.67 million.
The insiders hold 27.41% of the company’s shares while institutions hold 36.09%. The data shows that short shares as of Feb 29, 2024, stood at 14.4 million at a short ratio of 10.52. This represents a 8.61% short interest in shares outstanding on Feb 29, 2024. Shares short rose in February from the previous month at 12.8 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 10.11% up in year-to-date price movement.
